Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Michael Lim MD

Michael Lim MD

Associate Professor of Neurosurgery; Director of Brain Tumor Immunotherapy, The Johns Hopkins Hospital, Baltimore, Maryland

Dr. Michael Lim is an Associate Professor of Neurosurgery, Oncology and Radiation Oncology at Johns Hopkins.  Dr. Lim’s surgical interest is in both benign and malignant brain tumors, with a particular interest in gliomas. He is the Director of the Brain Tumor Immunotherapy Program at Johns Hopkins.   Dr. Lim’s primary research interest is developing immune-based therapies against brain tumors.  His research laboratory is focused on understanding the mechanisms of immune evasion by primary brain tumors.   Dr. Lim’s laboratory focuses particularly in checkpoint inhibitors and signaling pathways behind immune modulation.  In addition to running a laboratory, he also directs the immunotherapy clinical trials program at Johns Hopkins.  He currently serves as the principal investigator of several large multi-center brain tumor immunotherapy clinical trials. 

Disclosures

Dr. Lim reported the following disclosures:
  • Research Support: Arbor, Aegenus, Altor, BMS, Immunocellular, Celldex, Accuray
  • Consultant:Aegenus, BMS, Regeneron, Oncorus, Boston Biomedical, Tocagen
  • Non-research: Consultant - Stryker, Baxter

Recent Contributions to PracticeUpdate:

  1. Important Presentations From SNO 2019
  2. Nivolumab Versus Bevacizumab for Recurrent GBM
  3. Phase 0 Immunotherapy Clinical Trials in Neuro-Oncology
  4. Stereotactic Radiosurgery vs Whole Brain Radiation for Patients With Four or More Brain Metastases
  5. Biological Basis for Low Responses to Immunotherapy in GBM
  6. Current Status of Immunotherapy for GBM
  7. Checkpoint Inhibitors in Combination With Novel Therapies for Recurrent GBM
  8. Evidence-Based Use of Immunotherapy in GBM: An Expert Review
  9. New Data on Immune Checkpoint Inhibitors in Glioblastoma From SNO 2017

Recently Updated